Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd (Nasdaq: IVVD) granted stock options as inducement awards to new employees. On June 1, 2026, 17 newly hired non-executive employees received options to purchase an aggregate of 513,500 shares under the 2026 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4).
The options have a $1.22 per share exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting monthly, subject to continuous service.
Invivyd (Nasdaq: IVVD) has completed enrollment in the upsized Phase 3 DECLARATION trial of VYD2311, an investigational monoclonal antibody to prevent symptomatic COVID-19 in adults and adolescents. The BLA-enabling, randomized, placebo-controlled study tests single and monthly intramuscular dosing. Top-line results are expected in approximately late Q3 2026.
Invivyd (Nasdaq: IVVD) will join several June 2026 investor events, including the Jefferies Global Healthcare Conference in New York, the H.C. Wainwright “HCW @ Home” Series, and BTIG Infectious Disease Day 2026.
Fireside chats will be webcast and archived on Invivyd’s investor website.
Invivyd (Nasdaq: IVVD) reported Q1 2026 PEMGARDA net product revenue of $13.7 million, up 22% from Q1 2025. Cash and equivalents were $184.2 million plus ~$20 million raised via ATM in April. R&D and SG&A rose sharply, driving a $41.4 million net loss, while pivotal VYD2311 DECLARATION data are now expected in Q3 2026. The company advanced VYD2311 programs, received multiple FDA interactions, and expanded its pipeline with measles candidate VMS063 and RSV candidate VBY329.
Invivyd (Nasdaq: IVVD) reported new analysis of early systemic side effects comparing COVID-19 monoclonal antibody adintrevimab with mRNA and protein vaccines. In the EVADE trial, Grade 2/3 systemic adverse events in the first seven days were 2% for monoclonal antibody versus 1% for placebo, compared with 91.6% for mRNA and 83.6% for protein vaccine in Sanofi’s COMPARE study. The MedRxiv preprint also models total symptom days from both reactogenicity and breakthrough infections. Invivyd plans the LIBERTY head-to-head trial evaluating systemic symptoms after mRNA vaccination versus low-dose VYD2311.
Invivyd (Nasdaq: IVVD) will host a webcast and conference call on May 14, 2026 at 8:30 a.m. ET to discuss first quarter 2026 financial results and provide a corporate update. A replay will be available on the company investor website about two hours after the call.
Analysts may register to participate in the Q&A; attendees are advised to join 15 minutes early.
Invivyd (Nasdaq: IVVD) announced on May 1, 2026 the grant of inducement stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4) and the Invivyd 2026 Inducement Plan.
The company granted options to 17 non-executive employees for an aggregate of 731,000 shares, at a per‑share exercise price of $1.52 (closing price on the grant date). Each option vests over four years (25% after one year, then monthly) and has a 10‑year term, subject to the plan and continued service.
Invivyd (Nasdaq: IVVD) announced Chairman Marc Elia will speak at the POLITICO Health Care Summit on April 21, 2026 from 11:30 AM–12:00 PM ET. The session will discuss viral disease prevention and the role of monoclonal antibodies in advancing public health. The event will be live streamed 9:00 AM–1:00 PM ET.
Invivyd (Nasdaq: IVVD) reported a DECLARATION Phase 3 sample-size re-estimation that upsizes the trial by ~500 subjects and shifts expected top-line timing modestly to Q3 2026. The company aligned with the FDA on an initial pediatric study plan and advanced VMS063, a potent measles monoclonal antibody, toward IND-enabling work with target IND readiness in late 2026.
VMS063 shows low ng/mL and high-pg/mL neutralization across circulating measles lineages, is half-life extended, and targets a conserved measles F protein epitope.
Invivyd (Nasdaq: IVVD) launched a national education campaign, Antibodies for Any Body, in partnership with skier Lindsey Vonn on April 7, 2026. The campaign debut includes AntibodiesforAnyBody.com and an interactive Wellness Assessment to explain antibodies and lifestyle links to immune health.
The site offers accessible resources about antibody function and how sleep, nutrition, and activity may support immune protection; visitors are encouraged to consult their doctor about personalized habits.